Princeton OKs Bexsero vaccination campaign; Mylan recalls 480K bottles of blood-pressure med;

@FiercePharma: Monday's most-read story: Takeda's new outsider CFO charged with $1B cost-cutting plan. More | Follow @FiercePharma

@EricPFierce: Patheon, DSM join forces in $2.6B deal, to create no name company with global reach. More | Follow @EricPFierce

@CarlyHFierce: U.S. approves drug tracking, compound pharmacy oversight law. Story from FiercePharmaManufacturing | Follow @CarlyHFierce

> Princeton University decided to offer Novartis' ($NVS) meningitis B vaccination Bexsero to students to help quell a campus outbreak; approved in Europe and Australia, Bexsero will be imported to the U.S. under special rules for products not yet generally cleared by the FDA. Report

> Generics maker Mylan ($MYL) recalled more than 480,000 bottles of its blood pressure medication amlodipine besylate because their active ingredient didn't meet manufacturing standards. Report

> Teva Pharmaceutical Industries ($TEVA) launched two branded drugs for cancer patients, Lonquex and Granix, in Germany and the U.S., respectively. Report

> Gilead Sciences ($GILD) won European approval for its HIV drug Vitekta after the FDA refused to clear it for sale in April. Report (sub. req.)

> Merck ($MRK) said it would bring its campaign to reduce pregnancy-related deaths, now active in Africa, to the U.S., where rates have sharply increased. Report

> Medicare's failure to track doctors' prescribing habits wastes billions on unnecessary brand-name drugs, a study found. Report

> Teva teamed up with an Australian supplements company, via its joint venture with Procter & Gamble ($PG), to expand its range of products globally. Report

Medical Device News

@FierceMedDev: Study: Medtronic next-gen pacer tech achieves atrial fibrillation delay. More | Follow @FierceMedDev

@MarkHFierce: Cardiovascular Systems wants to sell 2.1M shares in a public offering. Simply put: expansion requires funding. Story | Follow @MarkHFierce

@MichaelGFierce: Spoke to MIT's Dr. Robert Langer about drug delivery and nanotech. Story in tomorrow's FierceDrugDelivery report. | Follow @MichaelGFierce

> Congress faces pushback over proposed Medicare medical imaging cuts. Item

> Medtronic's otherwise stellar Q2 stained by spinal revenue declines. More

> NEJM: Stents don't beat drugs in treating clogged renal arteries. Article

Biotech News

@FierceBiotech: Gilead charts PhIII success for leukemia drug as J&J showdown awaits. More | Follow @FierceBiotech

@JohnCFierce: Check out my webinar Thursday morning with Toni Ribas and Carol Gallagher on targeted cancer drugs. More | Follow @JohnCFierce

@DamianFierce: AstraZeneca just can't wait to get to Cambridge, plans to deploy 400 scientists to get R&D ball rolling. Story | Follow @DamianFierce

@EmilyMFierce: As resistance rises, one MIT team is investigating how a bacteria-derived toxin could help design new antibiotics. Article | Follow @EmilyMFierce

> Merck spotlights promising data on 'breakthrough' cancer immunotherapy MK-3475. More

> Amgen's cancer-fighting virus boosts melanoma survival in PhIII study. Article

Pharma Manufacturing News

> Glaxo to use new technology in India plant. Report

> 2 Puerto Rico plants up next in Merck job-whacking plan. Story

> J&J, Merck KGaA roll out new China plant projects. Article

> DSM, Patheon join up in $2.6B deal. More

> U.S. approves drug tracking, compound pharmacy oversight law. Story

> Mylan recalls 480,000 bottles of blood pressure med. Item

Biotech Research News

> Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. More

> Oxford, MRC Technology team up on migraine drug discovery. Item

> First-ever 'mini-kidney' organs created from human stem cells. Story

> Bacteria-derived toxin could provide design for new antibiotics. Article

> Herb-based compounds improve learning, memory in Alzheimer's mice. News

> Compound that targets fat-burning mechanism discovered. Report

And Finally... AstraZeneca ($AZN) selected the architecture firm Herzog & de Meuron to design its new hub and headquarters in Cambridge, U.K. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.